Obesity

New England Journal of Medicine

Volumn 346, Issue 8, 2002, Pages 591-602

  Yanovski, Susan Z ^a   Yanovski, Jack A ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; AMFEPRAMONE; ANTIOBESITY AGENT; BENZPHETAMINE; CAFFEINE; CHITOSAN; CHROMIUM PICOLINATE; DEXFENFLURAMINE; EPHEDRA EXTRACT; FENFLURAMINE; FLUOXETINE; LINOLEIC ACID; METFORMIN; PHENDIMETRAZINE; PHENDIMETRAZINE TARTRATE; PHENTERMINE; PHENTERMINE RESIN; PRELU 2; RECOMBINANT LEPTIN; SERTRALINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG; X TROZINE;

AGITATION; APPETITE DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG COST; DRUG INDUCED DISEASE; DRUG MECHANISM; GLAUCOMA; HUMAN; HYPERTENSION; HYPERTHYROIDISM; INTESTINE ABSORPTION; NORADRENALIN RELEASE; NUTRIENT; OBESITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SEROTONIN RELEASE; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ADULT; ALGORITHMS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BEHAVIOR THERAPY; CHILD; CLINICAL TRIALS; DIETARY FATS; DIETARY SUPPLEMENTS; DRUG COMBINATIONS; EVIDENCE-BASED MEDICINE; EXERCISE; FEMALE; HUMANS; INTESTINAL ABSORPTION; MALE; OBESITY; PHYTOTHERAPY; PLANT PREPARATIONS; WEIGHT LOSS;

EID: 0037148922     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra012586     Document Type: Review

References (108)

1. Overweight and obesity in the United States: Prevalence and trends, 1960-1994
2. Overweight prevalence and trends for children and adolescents: The National Health and Nutrition Examination Surveys, 1963 to 1991
3. From the Centers for Disease Control and Prevention: Update: Prevalence of overweight among children, adolescents, and adults - United States, 1988-1994
4. Over-weight, obesity, and health risk
5. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - The evidence report
6. Growing the market for anti-obesity drugs
7. Use of prescription weight loss pills among U.S. adults in 1996-1998
8. Prevalence of attempting weight loss and strategies for controlling weight
9. Behavioral treatment of obesity
10. Behavioral strategies of individuals who have maintained long-term weight losses
11. What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes
12. Effect of degree of weight loss on health benefits
13. Methods for voluntary weight loss and control
14. Historical framework for the development of ideas about obesity
15. Behavioral control of overeating: 1967
16. Current and potential drugs for treatment of obesity
17. Long-term weight control study: Conclusions
18. Long-term weight control study. VII (weeks 0 to 210). Serum lipid changes
19. Long-term weight control study. VI. Individual participant response patterns
20. Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication
21. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase
22. Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine
23. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise
24. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo
25. Long-term weight control: The National Heart, Lung, and Blood Institute funded multimodal intervention study
26. Long-term pharmacotherapy in the management of obesity
27. Long-term use of appetite suppressant medication: Rationale and recommendations
28. Valvular heart disease associated with fenfluramine-phentermine
29. Thermogenic drugs as a strategy for treatment of obesity
30. Clinical studies with mazindol
31. Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity
32. A comparative trial of different regimens of fenfluramine and phentermine in obesity
33. Long-term use of diethylpropion in obesity
34. Comparison of continuous and intermittent anorectic therapy in obesity
35. The long-term management of obesity in general practice
36. Obesity drugs and the heart
37. Phenylpropanolamine and the risk of hemorrhagic stroke
38. Clinical studies with dexfenfluramine: From past to future
39. Fluoxetine: A randomized clinical trial in the maintenance of weight loss
40. Fluoxetine: A randomized clinical trial in the treatment of obesity
41. Sertraline and relapse prevention training following treatment by very-low-calorie diet: A controlled clinical trial
42. Absence of cardiac valve dysfunction in obese patients treated with sibutramine
43. Sibutramine for obesity
44. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity
45. Sibutramine produces dose-related weight loss
46. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus
47. Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity
48. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: A 1-year, double-blind, placebo-controlled, multicenter trial
49. Effect of sibutramine on weight maintenance after weight loss: A randomised trial
50. Long-term maintenance of weight loss after a very- low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine
51. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: A randomised, double-blind, placebo-controlled study
52. Orlistat, a new lipase inhibitor for the management of obesity
53. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial
54. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A 1-y study
55. Randomised placebo-controlled trial of orlistar for weight loss and prevention of weight regain in obese patients
56. Role of orlistat in the treatment of obese patients with type 2 diabetes: A 1-year randomized double-blind study
57. Orlistat in the long-term treatment of obesity in primary care settings
58. Regulatory environment for dietary supplements and botanicals targeted to weight loss
59. Alternative treatments for weight loss: A critical review
60. Herbal ephedra/caffeine for weight loss: A 6-month safety and efficacy trial
61. An herbal supplement containing Ma Huang-Guarana for weight loss: A randomized, double-blind trial
62. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: A double blind trial
63. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity: A double-blind multi-centre trial in general practice
64. Ephedrine, caffeine and aspirin: Safety and efficacy for treatment of human obesity
65. Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture
66. Content versus label claims in ephedra-containing dietary supplements
67. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids
68. The FDA, regulation, and the risk of stroke
69. Bupropion SR shows promise as an effective obesity treatment
70. Clinical trial using bupropion SR with a moderate-intensity lifestyle intervention
71. Topiramate, a novel antiepileptic drug, reduces body weight and food intake in obesity
72. Treatment of affective disorder and obesity with topiramate
73. Treatment of binge-eating disorder with topiramate: A clinical case series
74. Topiramate
75. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution
76. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
77. The Diabetes Prevention Program: Baseline characteristics of the randomized cohort
78. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome
79. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes
80. Biguanides and NIDDM
81. Metformin
82. Weight-reducing effects of the plasma protein encoded by the obese gene
83. Congenital leptin deficiency is associated with severe early-onset obesity in humans
84. Effects of recombinant leptin therapy in a child with congenital leptin deficiency
85. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial
86. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men
87. New leptin trial begins
88. Axokine causes significant weight loss in severely and morbidly obese subjects
89. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism
90. Drug development update
91. Benefits of lifestyle modification in the pharmacologic treatment of obesity: A randomized trial
92. Long-term weight loss with sibutramine: A randomized controlled trial
93. The "phen-pro" diet drug combination is not associated with valvular heart disease
94. Long-term drug treatment of obesity in a private practice setting
95. Addition of orlistat to long term phentermine treatment for obesity
96. Open treatment of overweight binge eaters with phentermine and fluoxetine as an adjunct to cognitive-behavioral therapy
97. Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters
98. Comparison of serotonin agonists in combination with phentermine for treatment of obesity
99. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: A placebo-controlled trial
100. Ten-year outcomes of behavioral family-based treatment for childhood obesity
101. A pilot study of the efficacy of orlistat in overweight adolescents
102. Are drugs the answer to childhood obesity?
103. Safety and efficacy of treatment with an ephedrine/caffeine mixture: The first double-blind placebo-controlled pilot study in adolescents
104. Hypothalamic obesity caused by cranial insult in children: Altered glucose and insulin dynamics and reversal by a somatostatin agonist